Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $37.1 million.

  • 4D Molecular Therapeutics' Total Current Liabilities rose 25.94% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year increase of 25.94%. This contributed to the annual value of $29.1 million for FY2024, which is 53.81% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Total Current Liabilities stood at $37.1 million for Q3 2025, which was up 7.01% from $34.7 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Total Current Liabilities peaked at $37.1 million during Q3 2025, and registered a low of $9.9 million during Q2 2021.
  • For the 3-year period, 4D Molecular Therapeutics' Total Current Liabilities averaged around $23.2 million, with its median value being $19.4 million (2024).
  • In the last 5 years, 4D Molecular Therapeutics' Total Current Liabilities dropped by 13.11% in 2022 and then spiked by 78.72% in 2025.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Total Current Liabilities stood at $16.3 million in 2021, then fell by 3.72% to $15.7 million in 2022, then grew by 20.47% to $19.0 million in 2023, then spiked by 53.81% to $29.1 million in 2024, then increased by 25.94% to $37.1 million in 2025.
  • Its Total Current Liabilities was $37.1 million in Q3 2025, compared to $34.7 million in Q2 2025 and $26.9 million in Q1 2025.